醋酸乌利司他

醋酸乌利司他
临床资料
商品名（英语：Drug nomenclature）	Ella, EllaOne, Esmya, others
其他名称	CDB-2914; 11β-[4-(Dimethylamino)phenyl]-17α-acetoxy-19-norpregna-4,9-diene-3,20-dione
AHFS/Drugs.com	Monograph
核准状况	美 DailyMed: acetate Ulipristal acetate;
给药途径	口服给药
药物类别（英语：Drug class）	选择性孕酮受体调节剂（英语：Selective progesterone receptor modulator）
ATC码	G03AD02 (WHO) G03XB02;
法律规范状态
法律规范	澳：限医生处方（S4）; 欧：Rx-only; 英：处方药（℞-only） (POM)/ P; 美：处方药（℞-only）;
药物动力学数据
生物利用度	几乎100%
血浆蛋白结合率	96.7–99.5%
药物代谢	可能是CYP3A4
生物半衰期	32小时
排泄途径	约90%由粪便
识别信息
	IUPAC命名法 [(8S,11R,13S,14S,17R)-17-acetyl-11-[4-(dimethylamino)phenyl]-13-methyl-3-oxo-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate; ;
CAS号	126784-99-4
PubChem CID	130904;
IUPHAR/BPS	7460;
DrugBank	DB08867 ;
ChemSpider	115762 ;
UNII	YF7V70N02B;
KEGG	D09687;
ChEBI	CHEBI:71025 ;
ChEMBL	ChEMBL260538 ;
CompTox Dashboard（英语：CompTox Chemicals Dashboard） (EPA)	DTXSID30155294 ;
ECHA InfoCard	100.207.349
化学信息
化学式	C30H37NO4
摩尔质量	475.63 g·mol−1
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES CC(=O)OC4(C(C)=O)CCC3C1CCC2=CC(=O)CCC2=C1C(CC34C)c5ccc(N(C)C)cc5;
	InChI InChI=1S/C30H37NO4/c1-18(32)30(35-19(2)33)15-14-27-25-12-8-21-16-23(34)11-13-24(21)28(25)26(17-29(27,30)3)20-6-9-22(10-7-20)31(4)5/h6-7,9-10,16,25-27H,8,11-15,17H2,1-5H3/t25-,26+,27-,29-,30-/m0/s1 ; Key:OOLLAFOLCSJHRE-ZHAKMVSLSA-N ;

醋酸乌利司他是用于紧急避孕和子宫肌瘤的口服药物^[1] ^[7] ^[8]。用于紧急避孕时，需在性交后 120 小时内使用^[1]。用于子宫肌瘤时，可能需要服用至少 6 个月^[9]。

常见副作用包括头痛、恶心、疲倦和腹痛^[1]。已怀孕者不宜使用此药^[1]。它属于选择性孕酮受体调节剂（英语：Selective progesterone receptor modulator）（Selective progesterone receptor modulator，SPRM）^[1]。作用机转是阻止孕酮作用，而停止排卵^[10]。

醋酸乌利司他于 2010 年在美国取得医疗使用许可^[1]。名列世界卫生组织基本药物标准清单^[11]。为提高药物可及性，有人建议为所有有怀孕风险的女性提供处方，以便于必要时使用^[10]。

参考文献

^ ^1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 Ulipristal Acetate. The American Society of Health-System Pharmacists. [8 December 2017]. （原始内容存档于10 December 2017）. "Ulipristal Acetate". The American Society of Health-System Pharmacists. Archived from the original on 10 December 2017. Retrieved 8 December 2017.
^ Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].
^ ellaOne 30 mg - Summary of Product Characteristics (SmPC). (emc). 1 July 2021 [28 February 2022].
^ Esmya 5 mg Tablets (ulipristal acetate) - Summary of Product Characteristics (SmPC). (emc). 17 February 2021 [28 February 2022].
^ Ella- ulipristal acetate tablet. DailyMed. 1 November 2023 [26 September 2024].
^ ellaOne EPAR. European Medicines Agency (EMA). 3 June 2009 [8 July 2020].
^ Garnock-Jones, KP; Duggan, ST. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.. Drugs. October 2017, 77 (15): 1665–1675. PMID 28900897. S2CID 207489367. doi:10.1007/s40265-017-0812-3.
^ Ulipristal - Drugs.com. Drugs.com. [14 December 2017]. （原始内容存档于14 December 2017）.
^ British national formulary : BNF 69 69. British Medical Association. 2015: 510, 560. ISBN 9780857111562.
^ ^10.0 ^10.1 Likis, Frances E. Women's Gynecologic Health. Jones & Bartlett Publishers. 2016: 243. ISBN 9781284076028. （原始内容存档于10 December 2017）（英语）.
^ World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[AHFS2017-1] 1.0 ^1.1 ^1.2 ^1.3 ^1.4 ^1.5 ^1.6 ^1.7 Ulipristal Acetate. The American Society of Health-System Pharmacists. [8 December 2017]. （原始内容存档于10 December 2017）. "Ulipristal Acetate". The American Society of Health-System Pharmacists. Archived from the original on 10 December 2017. Retrieved 8 December 2017.

[2] Prescription medicines: registration of new chemical entities in Australia, 2015. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023].

[3] One 30 mg - Summary of Product Characteristics (SmPC). (emc). 1 July 2021 [28 February 2022].

[4] Esmya 5 mg Tablets (ulipristal acetate) - Summary of Product Characteristics (SmPC). (emc). 17 February 2021 [28 February 2022].

[5] Ella- ulipristal acetate tablet. DailyMed. 1 November 2023 [26 September 2024].

[ellaOne_EPAR-6] One EPAR. European Medicines Agency (EMA). 3 June 2009 [8 July 2020].

[7] Garnock-Jones, KP; Duggan, ST. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.. Drugs. October 2017, 77 (15): 1665–1675. PMID 28900897. S2CID 207489367. doi:10.1007/s40265-017-0812-3.

[Drugs.com-8] Ulipristal - Drugs.com. Drugs.com. [14 December 2017]. （原始内容存档于14 December 2017）.

[BNF69-9] British national formulary : BNF 69 69. British Medical Association. 2015: 510, 560. ISBN 9780857111562.

[Li2016-10] 10.0 ^10.1 Likis, Frances E. Women's Gynecologic Health. Jones & Bartlett Publishers. 2016: 243. ISBN 9781284076028. （原始内容存档于10 December 2017）（英语）.

[WHO21st-11] World Health Organization. World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

[1]

[7]

[8]

[9]

[2]

[6]

[3]

[4]

[5]

[10]

[11]